THE EXPERIENCE AND RESULTS OF CYTOREDUCTIVE SURGERY AND HIPEC USED IN ADVANCED OVARIAN CANCER

Keywords: ovarian cancer, treatment, HIPEC, cytoreduction, chemotherapy

Abstract

The research object was life quality of patients with ovarian cancer after complex treatment. Nowadays cytoreductive surgery and HIPEC is the mainstay of management of advanced stages ovarian cancer.

Description of the problem: study was conducted to assess the effectiveness of combined treatment in IIIA-IIIC ovarian cancer, its impact on quality of life.

Main scientific results: 37 patients of main group (CRS + HIPEC) were compared with 25 patients of control group (surgery + systemic chemotherapy). The quality of life was assessed with Medical Outcomes Study 36-Item Short Form Health Survey (SF-36). Comparative analysis of quality of life 6 months after treatment completion did not show significant statistical difference. Combination of cytoreduction with HIPEC improves quality of life in patients with ovarian cancer, is tolerated better and has less systemic toxicities than systemic chemotherapy.

The area of practical use of research results: hyperthermic intraperitoneal chemotherapy is performed for patients suffering from malignant tumors of the abdominal cavity, including metastatic colon cancer, ovarian cancer, stomach cancer, pseudomyxoma, mesothelioma, rhabdomyosarcoma, and some other types of oncology.

Innovative technological product: combination of cytoreduction with HIPEC improves quality of life in patients with ovarian cancer.

Scope of application of an innovative technological product: HIPEC is an innovative treatment option for advanced cancer that has spread to the abdominal cavity (carcinomatosis) and has not gone beyond it.

Downloads

Download data is not yet available.

Author Biographies

Oleksandr Bondar, Odessa State Medical UniversityUniversity clinic of Odessa Medical University

Department of X-ray diagnostics, radiotherapy and radiation medicine with a course of oncology

Andriy Rybin, Odesa National Medical University

Department of X-ray diagnostics, radiotherapy and radiation medicine with a course of oncology

References

Bulletin of National Cancer Registry of Ukraine (2019). Kyiv, 21. Available at: http://www.ncru.inf.ua/publications/BULL_21/index_e.htm

Global Cancer Observatory. Available at: https://gco.iarc.fr/

Cotte, E., Glehen, O., Mohamed, F., Lamy, F., Falandry, C., Golfier, F., Gilly, F. N. (2007). Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients. World Journal of Surgery, 31 (9), 1813–1820. doi: http://doi.org/10.1007/s00268-007-9146-8

Parson, E. N., Lentz, S., Russell, G., Shen, P., Levine, E. A., Stewart, J. H. (2011). Outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface dissemination from ovarian neoplasms. The American Journal of Surgery, 202 (4), 481–486. doi: http://doi.org/10.1016/j.amjsurg.2011.02.004

Di Giorgio, A., Naticchioni, E., Biacchi, D., Sibio, S., Accarpio, F., Rocco, M. et. al. (2008). Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer, 113 (2), 315–325. doi: http://doi.org/10.1002/cncr.23553

Bakrin, N., Classe, J. M., Pomel, C., Gouy, S., Chene, G., Glehen, O. (2014). Hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer. Journal of Visceral Surgery, 151 (5), 347–353. doi: http://doi.org/10.1016/j.jviscsurg.2014.07.005

Onda, T., Kobayashi, H., Nakanishi, T., Hatae, M., Iwasaka, T., Konishi, I. et. al. (2009). Feasibility study of neoadjuvant chemotherapy followed by interval debulking surgery for stage III/IV ovarian, tubal, and peritoneal cancers: Japan Clinical Oncology Group Study JCOG0206. Gynecologic Oncology, 113 (1), 57–62. doi: http://doi.org/10.1016/j.ygyno.2008.12.027

Di Giorgio, A., Naticchioni, E., Biacchi, D., Sibio, S., Accarpio, F., Rocco, M. et. al. (2008). Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer, 113 (2), 315–325. doi: http://doi.org/10.1002/cncr.23553

Chua, T. C., Yan, T. D., Saxena, A., Morris, D. L. (2019). Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure? A systematic review of morbidity and mortality. Annals of Surgery, 249 (6), 900–907. doi: http://doi.org/10.1097/sla.0b013e3181a45d86

Bristow, R. E., Tomacruz, R. S., Armstrong, D. K., Trimble, E. L., Montz, F. J. (2002). Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis. Journal of Clinical Oncology, 20 (5), 1248–1259. doi: http://doi.org/10.1200/jco.2002.20.5.1248


👁 94
⬇ 86
Published
2020-10-31
How to Cite
Bondar, O., & Rybin, A. (2020). THE EXPERIENCE AND RESULTS OF CYTOREDUCTIVE SURGERY AND HIPEC USED IN ADVANCED OVARIAN CANCER. ScienceRise, (5), 19-23. https://doi.org/10.21303/2313-8416.2020.001458
Section
Innovative technologies in healthcare